Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival.
Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival.
复制标题
DOI：
10.1371/journal.pone.0197081
复制
发表时间：
2018
期刊：
影响因子：
3.7
通讯作者：
Abramson DH
中科院分区：
文献类型：
--
作者：
Francis JH;Levin AM;Zabor EC;Gobin YP;Abramson DH
报告视网膜母细胞瘤眼部动脉化疗（OAC）治疗的疾病和治疗相关变量、无复发生存率和眼部存活率之间的关联。张后研究。2006年5月至2017年2月期间，所有眼睛都在纪念斯隆凯特琳癌症中心接受了视网膜母细胞瘤的OAC治疗。这项回顾性研究包括452只接受OAC治疗的视网膜母细胞瘤眼。采用Kaplan-Meier法估计无复发生存期（RFS）、无进展生存期（PFS）和眼生存期（OcS），采用Cox回归估计风险比。将玻璃体前化疗时期治疗的眼与玻璃体内化疗时期治疗的眼分开分析。在中位23.6个月的随访中记录无复发生存期、眼部生存期、与复发疾病风险的关联以及治疗特征。1年的OcS、PFS和RFS在玻璃体腔前分别为96% （95% CI 93-99%）、88% （95% CI 88-94%）和74% (95% CI 67-81%)，在玻璃体腔内分别为96% （95% CI 94-99%）、93% （95% CI 89-96%）和78% （95% CI 72-83%）。玻璃体种子的存在与玻璃体前时代复发风险增加有关，而与玻璃体时代无关。两次OAC手术间隔时间较长与复发风险增加有关，大部分OAC手术经眼动脉进入与两个时期复发风险降低有关。在最初接受眼动脉化疗的眼睛中，大约有四分之一的眼睛会出现复发性疾病，其中大多数在OAC完成后的第一年内复发。尽管如此，这些眼睛还是有很大的机会被抢救出来。在出现玻璃体种子的眼睛中，玻璃体内注射有助于减少未来玻璃体的复发。大部分药物输注通过非眼动脉途径或OAC间隔时间较长的眼睛更容易复发，可能需要更密切的监测。
To report associations between disease- and treatment-related variables and rates of recurrence-free survival and ocular survival in eyes treated with ophthalmic artery chemosurgery (OAC) for retinoblastoma. Pre-post study. All eyes treated with OAC for retinoblastoma at Memorial Sloan Kettering Cancer Center between May 2006 and February 2017. This retrospective review included 452 retinoblastoma eyes treated with OAC. The Kaplan-Meier method was used to estimate recurrence-free survival (RFS), progression-free survival (PFS) and ocular survival (OcS), and Cox regression was used to estimate hazard ratios. Eyes treated in the pre-intravitreous chemotherapy era were analyzed separately from eyes treated in the intravitreal era. Recurrence-free survival, ocular survival, associations with risk of recurrence Disease and treatment characteristics were recorded over a median 23.6 month follow-up. One-year OcS, PFS and RFS were 96% (95% CI 93–99%), 88% (95% CI 88–94%) and 74% (95% CI 67–81%) in the pre-intravitreal era and 96% (95% CI 94–99%), 93% (95% CI 89–96%) and 78% (95% CI 72–83%) in the intravitreal era, respectively. Presence of vitreous seeds was associated with increased risk of recurrence in the pre-intravitreal era but not in the intravitreal era. Longer time interval between OAC sessions was associated with increased risk of recurrence and majority OAC access via the ophthalmic artery was associated with decreased risk of recurrence in both eras. Approximately a quarter of eyes initially treated with ophthalmic artery chemosurgery develop recurrent disease, with the majority of recurrences within the first year following completion of OAC. Despite this, these eyes have a very good chance of salvage. In eyes with vitreous seeds at presentation, intravitreal injections are useful in minimizing future vitreous recurrence. Eyes that receive the majority of drug infusions via non-ophthalmic artery routes or greater interval between OAC are more likely to recur and might warrant closer monitoring.
登录
查看更多内容
影响因子：
3.7
作者：
Gobin YP;Dunkel IJ;Marr BP;Francis JH;Brodie SE;Abramson DH
通讯作者：
Abramson DH
晚期单侧视网膜母细胞瘤：眼科化学外科对MSKCC涂料率和患者存活的影响。
影响因子：
3.7
作者：
Abramson DH;Fabius AW;Issa R;Francis JH;Marr BP;Dunkel IJ;Gobin YP
通讯作者：
Gobin YP
影响因子：
13.7
作者：
Abramson, David H.;Dunkel, Ira J.;Gobin, Y. Pierre
通讯作者：
Gobin, Y. Pierre
影响因子：
3.7
作者：
Dunkel, Ira J.;Shi, Weiji;Abramson, David H.
通讯作者：
Abramson, David H.
影响因子：
4.1
作者：
Abdelhakim, Aliaa H.;Francis, Jasmine H.;Brodie, Scott E.
通讯作者：
Brodie, Scott E.